Drug intelligence / Profile preview

WJ05129

Development stage: Phase 2
Lead developer: Suzhou Junjing BioSciences
Modality: Small Molecules
Administration: Oral

Overview

WJ05129 is an orally administered small molecule inhibitor targeting Aurora kinase A (AURKA), a serine/threonine-protein kinase involved in cell division. It is being developed for the treatment of advanced malignant solid tumors, including locally advanced or metastatic disease. The drug is currently in Phase I/II clinical trials and has shown preclinical activity as an Aurora A inhibitor. Its primary developer is Suzhou Junjing BioSciences. The mechanism of action involves inhibition of Aurora kinase A, which plays a critical role in mitotic spindle formation and tumor cell proliferation.

Targets

AURKA (Aurora kinase A)

Beyond the preview

Go deeper on WJ05129.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ05129.

Explore the full profile